Clinical Trial Update: Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating interferon alfa therapy guided by Th17 profile for membranous nephropathy; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Interferon Alfa (interferon alfa)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Membranous Nephropathy | Phase 2 | Status: UNKNOWN